Makoto Yamamoto

We are pleased to announce that Makoto Yamamoto, CEO will present at “GTB / JBA / JETRO BioStartup Pitch – GTB BioStartup Connect”  on December 11, 2025 . This event is jointly hosted by the Greater Tokyo Biocommunity (GTB), Japan Bioindustry Association (JBA), and JETRO, bringing together leading seed to Series C drug discovery startups. Our presentation will highlight our novel nucleic acid technology that induces cancer cell death and activates cancer immunity , forming a next-generation...

Our CEO, Makoto Yamamoto, has been invited to present at the “Rising Biotech Challenge 2025 DEMO DAY,” hosted by Plug and Play Japan. This event serves as the culmination of the TOKYO SUTEAM life science accelerator program, where selected startups and academic teams will showcase their scientific achievements and commercialization plans. Tokyo Nucleic Acid Synthesis will present its next-generation cancer immunotherapy platform based on hairpin DNA technology triggered by tumor-specific...

TKG Therapeutics is pleased to announce its selection to present at the Biotech Showcase 2026 (Seed Showcase) in San Francisco. We will introduce our proprietary dual hairpin DNA platform, a novel approach that self-assembles within cancer cells triggered by onco-miRs. This platform simultaneously induces programmed cell death and activates an anti-tumor immune response. We look forward to connecting with investors, pharma partners, and innovators focused on advancing next-generation oncology...